CRZBF(CRZBF)
CRZBF
No analyst ratings available
No analyst price targets available for CRZBF
Analyst coverage may not be available for this symbol
No recent analyst actions
| Metric | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|
| Revenue Avg | $13.58B | $14.56B | $15.40B | $16.23B | $17.19B |
| Low | $13.31B | $14.07B | $14.99B | $15.79B | $16.73B |
| High | $13.70B | $14.89B | $15.64B | $16.48B | $17.46B |
| EBITDA Avg | $5.68B | $6.75B | $7.98B | $8.65B | $10.54B |
| Low | $5.51B | $6.55B | $7.74B | $8.38B | $10.21B |
| High | $5.78B | $6.87B | $8.13B | $8.80B | $10.74B |
| EBIT Avg | $4.83B | $5.89B | $7.09B | $7.72B | $9.58B |
| Low | $4.67B | $5.68B | $6.85B | $7.46B | $9.25B |
| High | $4.93B | $6.01B | $7.24B | $7.88B | $9.78B |
| Net Income Avg | $3.61B | $4.40B | $5.30B | $5.77B | $7.15B |
| Low | $3.48B | $4.24B | $5.11B | $5.57B | $6.90B |
| High | $3.68B | $4.49B | $5.40B | $5.88B | $7.30B |
| EPS Avg | $3.20 | $3.90 | $4.70 | $5.12 | $6.35 |
| Low | $3.09 | $3.76 | $4.53 | $4.94 | $6.13 |
| High | $3.27 | $3.98 | $4.79 | $5.22 | $6.48 |
| Analysts (Rev / EPS) | 12 / 1 | 12 / 1 | 5 / 1 | 10 / 1 | 6 / 1 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 |
|---|---|---|---|---|
| Revenue Avg | $3.41B | $3.55B | $3.66B | $3.64B |
| Low | $3.40B | $3.52B | $3.64B | $3.62B |
| High | $3.42B | $3.57B | $3.69B | $3.66B |
| EBITDA Avg | $1.52B | $1.52B | $1.82B | $1.84B |
| Low | $1.51B | $1.51B | $1.80B | $1.82B |
| High | $1.54B | $1.53B | $1.83B | $1.85B |
| EBIT Avg | $1.33B | $1.32B | $1.62B | $1.64B |
| Low | $1.32B | $1.31B | $1.61B | $1.62B |
| High | $1.34B | $1.33B | $1.63B | $1.65B |
| Net Income Avg | $993M | $985M | $1.21B | $1.22B |
| Low | $986M | $978M | $1.20B | $1.21B |
| High | $1.00B | $993M | $1.22B | $1.23B |
| EPS Avg | $0.80 | $0.80 | $0.98 | $0.99 |
| Low | $0.80 | $0.79 | $0.97 | $0.98 |
| High | $0.81 | $0.80 | $0.99 | $1.00 |
| Analysts (Rev / EPS) | 2 / 1 | 2 / 1 | 1 / 1 | 1 / 1 |